Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

CRISPR/Cas9-mediated editing of 1-aminocyclopropane-1-carboxylate oxidase1 enhances Petunia flower longevity.

Xu J, Kang BC, Naing AH, Bae SJ, Kim JS, Kim H, Kim CK.

Plant Biotechnol J. 2019 Jun 21. doi: 10.1111/pbi.13197. [Epub ahead of print]

2.

Complementary and Integrative Medicine Use in Individuals Seeking Conventional Medical Oncology Care in Chile: Prevalence and Patient Characteristics.

Lopez G, Salas CA, Cadiz F, Barriga C, Gonzalez P, Acevedo S, Raimilla P, Pincheira P, Naing A, Quiroga M.

J Glob Oncol. 2019 May;5:1-6. doi: 10.1200/JGO.18.00190.

3.

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.

Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.

J Immunother Cancer. 2019 May 3;7(1):118. doi: 10.1186/s40425-019-0604-2.

4.

In vitro propagation method for production of morphologically and genetically stable plants of different strawberry cultivars.

Naing AH, Kim SH, Chung MY, Park SK, Kim CK.

Plant Methods. 2019 Apr 13;15:36. doi: 10.1186/s13007-019-0421-0. eCollection 2019.

5.

Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors.

Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C.

Am J Cardiol. 2019 Apr 15;123(8):1351-1357. doi: 10.1016/j.amjcard.2019.01.013. Epub 2019 Jan 25.

PMID:
30765065
6.

Transcriptional activation of anthocyanin structural genes in Torenia 'Kauai Rose' via overexpression of anthocyanin regulatory transcription factors.

Junping X, Naing AH, Kim CK.

3 Biotech. 2018 Nov;8(11):476. doi: 10.1007/s13205-018-1505-7. Epub 2018 Nov 10.

PMID:
30456010
7.

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M.

Cancer Cell. 2018 Nov 12;34(5):775-791.e3. doi: 10.1016/j.ccell.2018.10.007.

PMID:
30423297
8.

Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.

Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP.

Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2.

PMID:
30410039
9.

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.

Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F.

Cancer. 2019 Feb 1;125(3):463-472. doi: 10.1002/cncr.31812. Epub 2018 Nov 1.

PMID:
30383888
10.

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A.

Gynecol Oncol. 2018 Dec;151(3):407-413. doi: 10.1016/j.ygyno.2018.10.008. Epub 2018 Oct 24.

PMID:
30366646
11.

Overexpression of RsMYB1 Enhances Anthocyanin Accumulation and Heavy Metal Stress Tolerance in Transgenic Petunia.

Ai TN, Naing AH, Yun BW, Lim SH, Kim CK.

Front Plant Sci. 2018 Sep 20;9:1388. doi: 10.3389/fpls.2018.01388. eCollection 2018.

12.

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.

Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S.

Oncotarget. 2018 Sep 7;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 7.

13.

Prevalence of Complementary Medicine Use in Patients With Cancer: A Turkish Comprehensive Cancer Center Experience.

Yalcin S, Hurmuz P, McQuinn L, Naing A.

J Glob Oncol. 2018 Sep;4:1-6. doi: 10.1200/JGO.2016.008896. Epub 2017 Apr 18.

14.

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS.

Oncotarget. 2018 Sep 4;9(69):33232-33243. doi: 10.18632/oncotarget.26075. eCollection 2018 Sep 4.

15.

Biomarkers of response to immune checkpoint blockade in cancer treatment.

Fujii T, Naing A, Rolfo C, Hajjar J.

Crit Rev Oncol Hematol. 2018 Oct;130:108-120. doi: 10.1016/j.critrevonc.2018.07.010. Epub 2018 Aug 3. Review.

PMID:
30196907
16.

Enhancement of Low pH Stress Tolerance in Anthocyanin-Enriched Transgenic Petunia Overexpressing RsMYB1 Gene.

Naing AH, Lee DB, Ai TN, Lim KB, Kim CK.

Front Plant Sci. 2018 Aug 21;9:1124. doi: 10.3389/fpls.2018.01124. eCollection 2018.

17.

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM.

Cancer Chemother Pharmacol. 2018 Nov;82(5):877-885. doi: 10.1007/s00280-018-3680-y. Epub 2018 Sep 4.

PMID:
30182147
18.

Differential expression of anthocyanin structural genes and transcription factors determines coloration patterns in gerbera flowers.

Naing AH, Park DY, Park KI, Kim CK.

3 Biotech. 2018 Sep;8(9):393. doi: 10.1007/s13205-018-1408-7. Epub 2018 Aug 30.

PMID:
30175030
19.

Roles of R2R3-MYB transcription factors in transcriptional regulation of anthocyanin biosynthesis in horticultural plants.

Naing AH, Kim CK.

Plant Mol Biol. 2018 Sep;98(1-2):1-18. doi: 10.1007/s11103-018-0771-4. Epub 2018 Aug 30. Review.

PMID:
30167900
20.

Overexpression of Rosea1 From Snapdragon Enhances Anthocyanin Accumulation and Abiotic Stress Tolerance in Transgenic Tobacco.

Naing AH, Ai TN, Lim KB, Lee IJ, Kim CK.

Front Plant Sci. 2018 Aug 15;9:1070. doi: 10.3389/fpls.2018.01070. eCollection 2018.

21.

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Subbiah V, Murthy R, Hong DS, Prins RM, Hosing C, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S, Piha-Paul S, Naing A, Conley AP, Benjamin RS, Kaur I, Bosch ML.

Clin Cancer Res. 2018 Aug 15;24(16):3845-3856. doi: 10.1158/1078-0432.CCR-17-2707. Epub 2018 Jul 17.

PMID:
30018119
22.

Challenges for Migrant and Cross-Border Populations With Diabetes Mellitus at Mae Tao Clinic in the Mae Sot-Myawaddy Border Region of Thailand and Myanmar.

Naing AL, Bakker M.

Int J Low Extrem Wounds. 2018 Sep;17(3):195-196. doi: 10.1177/1534734618788928. Epub 2018 Jul 16.

PMID:
30012032
23.

Anti-freezing-protein type III strongly influences the expression of relevant genes in cryopreserved potato shoot tips.

Seo JH, Naing AH, Jeon SM, Kim CK.

Plant Mol Biol. 2018 Jul;97(4-5):347-355. doi: 10.1007/s11103-018-0743-8. Epub 2018 Jun 4.

PMID:
29869190
24.

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.

Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V.

Lung Cancer. 2018 Jun;120:137-141. doi: 10.1016/j.lungcan.2018.03.020. Epub 2018 Apr 11.

25.

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, Subbiah V, Kurzrock R, Byers L, Westin S, Lim J, Bean S, Bass A, Nguyen L, Meric-Bernstam F, Hong D.

Br J Cancer. 2018 May;118(11):1419-1424. doi: 10.1038/s41416-018-0068-z. Epub 2018 Apr 26.

26.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

27.

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.

Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, Salathia NS, Hong DS, Naing A, Subbiah V, Piha-Paul SA, Bibikova M, Granger G, Barnes B, Shen R, Gutekunst K, Fu S, Tsimberidou AM, Lu C, Eng C, Moulder SL, Kopetz ES, Amaria RN, Meric-Bernstam F, Laird PW, Fan JB, Janku F.

Ann Oncol. 2018 Jun 1;29(6):1445-1453. doi: 10.1093/annonc/mdy119.

28.

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.

Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, Subbiah V.

Br J Cancer. 2018 Mar 20;118(6):763-769. doi: 10.1038/bjc.2017.480. Epub 2018 Feb 20.

29.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

30.

Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression.

Pucci M, Reclusa Asiáin P, Duréndez Sáez E, Jantus-Lewintre E, Malarani M, Khan S, Fontana S, Naing A, Passiglia F, Raez LE, Rolfo C, Taverna S.

Target Oncol. 2018 Apr;13(2):175-187. doi: 10.1007/s11523-018-0551-8.

PMID:
29374391
31.

Transcriptional control of anthocyanin biosynthesis genes and transcription factors associated with flower coloration patterns in Gerbera hybrida.

Naing AH, Lee JH, Park KI, Kim KO, Chung MY, Kim CK.

3 Biotech. 2018 Jan;8(1):65. doi: 10.1007/s13205-018-1099-0. Epub 2018 Jan 12.

32.

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V.

J Immunother Cancer. 2017 Dec 19;5(1):100. doi: 10.1186/s40425-017-0301-y.

33.

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F.

Mol Cancer Ther. 2018 Mar;17(3):671-676. doi: 10.1158/1535-7163.MCT-17-0673. Epub 2017 Dec 13.

34.

Involvement of Sodium Nitroprusside (SNP) in the Mechanism That Delays Stem Bending of Different Gerbera Cultivars.

Naing AH, Lee K, Kim KO, Ai TN, Kim CK.

Front Plant Sci. 2017 Nov 28;8:2045. doi: 10.3389/fpls.2017.02045. eCollection 2017.

35.

Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors.

Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS.

J Comput Assist Tomogr. 2018 May/Jun;42(3):357-364. doi: 10.1097/RCT.0000000000000686.

36.

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):638-646. doi: 10.1007/s10637-017-0534-0. Epub 2017 Nov 21.

PMID:
29159766
37.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

38.

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00002. Epub 2017 Sep 8.

39.

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A.

Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27.

PMID:
29075985
40.

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.

Möhrmann L, Huang HJ, Hong DS, Tsimberidou AM, Fu S, Piha-Paul SA, Subbiah V, Karp DD, Naing A, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM, Eng C, Kopetz ES, Skog J, Meric-Bernstam F, Janku F.

Clin Cancer Res. 2018 Jan 1;24(1):181-188. doi: 10.1158/1078-0432.CCR-17-2007. Epub 2017 Oct 19.

41.

Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model.

Shimizu Y, Furuya H, Tamashiro PM, Iino K, Chan OTM, Goodison S, Pagano I, Hokutan K, Peres R, Loo LWM, Hernandez B, Naing A, Chong CDK, Rosser CJ, Kawamori T.

Carcinogenesis. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.

42.

Synergistic Effect of Nano-Sliver with Sucrose on Extending Vase Life of the Carnation cv. Edun.

Park DY, Naing AH, Ai TN, Han JS, Kang IK, Kim CK.

Front Plant Sci. 2017 Sep 14;8:1601. doi: 10.3389/fpls.2017.01601. eCollection 2017.

43.

Role of Nano-silver and the Bacterial Strain Enterobacter cloacae in Increasing Vase Life of Cut Carnation 'Omea'.

Naing AH, Win NM, Han JS, Lim KB, Kim CK.

Front Plant Sci. 2017 Sep 13;8:1590. doi: 10.3389/fpls.2017.01590. eCollection 2017.

44.

Characterization of the role of sodium nitroprusside (SNP) involved in long vase life of different carnation cultivars.

Naing AH, Lee K, Arun M, Lim KB, Kim CK.

BMC Plant Biol. 2017 Sep 6;17(1):149. doi: 10.1186/s12870-017-1097-0.

45.

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F.

Breast Cancer Res. 2017 Aug 15;19(1):93. doi: 10.1186/s13058-017-0878-6.

46.

Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act.

Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS.

Clin Cancer Res. 2017 Jul 20. doi: 10.1158/1078-0432.CCR-16-3027. [Epub ahead of print]

47.

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.

Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S.

Oncotarget. 2017 May 16;8(20):33796-33806. doi: 10.18632/oncotarget.16840.

48.

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.

Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS.

J Immunother Cancer. 2017 Apr 18;5:35. doi: 10.1186/s40425-017-0238-1. eCollection 2017.

49.

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

Porta R, Borea R, Coelho A, Khan S, Araújo A, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R, Naing A, Hong D, Rolfo C.

Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23. Review.

PMID:
28427515
50.

First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.

Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS.

JCI Insight. 2017 Apr 20;2(8). pii: 90380. doi: 10.1172/jci.insight.90380. eCollection 2017 Apr 20.

Supplemental Content

Support Center